Skip to Main Content

One of biotech’s most respected entrepreneurs is betting the novel coronavirus won’t be the last deadly outbreak in his lifetime — and that vaccines won’t be enough to stop a future pandemic from bringing the world to a halt once more.

Tillman Gerngross, the Dartmouth bioengineering professor behind the biotech company Adimab, has founded a new firm dedicated to making antibodies that could protect against the novel coronavirus, called SARS-CoV-2, in addition to any future coronaviruses that might make the leap from animals to humans.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Today, front page story in the San Francisco Chronicle describes researchers finding that antibodies of Covid 19 fade away soner than expected, making a case for symptom treatment therapies.

Comments are closed.